Wearables
fromNew York Post
2 months agoEli Lilly stock surges 15% after clinical trial of weight loss pill shows it works like Ozempic
Eli Lilly's orforglipron shows significant weight loss for Type 2 diabetes patients, potentially rivaling injectable medications.
Lilly's shares surged 15% following promising clinical trial results for orforglipron.